In Brief: Edap TMS S.A
This article was originally published in The Gray Sheet
Executive Summary
Edap TMS S.A: FDA approval of a premarket approval application supplement for the firm's Prostatron version 2.5 transurethral microwave thermotherapy (TUMT) device for treatment of moderate to severe benign prostatic hyperplasia obstruction is expected "in the coming weeks," Edap's Eric Simon, CEO, stated Oct. 27 at the Oppenheimer conference in New York City. The PMA supplement was filed in April. Edap's Prostatron version 2.0 was approved in May 1996 for treatment of symptomatic BPH ("The Gray Sheet" May 13, 1996, I&W-1). Edap's product pipeline also includes a compact, mobile version of the Prostatron and high-intensity focused ultrasound technology for the minimally-invasive destruction of certain types of tumors ("The Gray Sheet" May 19, I&W-3)...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.